Chemical modulation of Kv7 potassium channels
Open accessThe DOI matches its Crossref record; 386 of the 386 references it cites were found in a registry or an index.
Abstract
This review describes the synthetic and medicinal chemistry of small molecule modulators of the voltage-gated Kv7 (KCNQ) potassium channels and the available data of their biological and clinical properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Natural-product leads like echinocystic acid and endogenous modulators such as dehydroepiandrosterone sulfate (DHEAS) expand chemotype space and suggest allosteric stabilization strategies that preserve physiological gating [267,269].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [267]
In the citing paper
“Structure-guided chemistry and in silico design have produced Kv7.2/7.3-biased agonists with order-of-magnitude potency gains over retigabine, improved pharmacokinetics, and reduced liabilities linked to earlier chemotypes [265,266,267].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [267]
In the citing paper
“Brain-penetrant exemplars such as Lu AA41178 and SCR2682, pan-Kv7 (KCNQ2–5) potassium-channel activators, demonstrate broad antiexcitability efficacy without major off-target activity, while clinical candidates including azetukalner and BHV-7000, Kv7.2/7.3-selective channel activators, aim to retain efficacy while avoiding pigmentation and urinary liabilities associated with earlier chemotypes [”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [267]
Citations
Cites
Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2008) · Chem. Soc. Rev. · doi:10.1039/b610213c · Cited by 7,570
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Ho Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Brown, R. H., & Al-Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,125
Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., Freeman, R., Truini, A., Attal, N., Finnerup, N. B., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.2 · Cited by 2,058
Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel
Sanguinetti, M. C., Curran, M. E., Zou, A., Shen, J., Specter, P. S., Atkinson, D. L., & Keating, M. T. (1996) · Nature · doi:10.1038/384080a0 · Cited by 1,764
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current
Barhanin, J., Lesage, F., Guillemare, E., Fink, M., Lazdunski, M., & Romey, G. (1996) · Nature · doi:10.1038/384078a0 · Cited by 1,614
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Research works printed but not linked: 24
- Dorange, 2011, Annu. Rep. Med. Chem., 46, 53
- Brueggemann, 2012, Am. J. Physiol., 302, 120
- Jepps, 2009, Am. J. Physiol., 297, 107
- Herrmann, 1987, Postgrad. Med. J., 63, 87
- Barrese, 2010, Clin. Pharmacol., 2, 225
- H. Yu , Z.Lin , K.Xu , X.Huang , S.Long , M.Wu , O. B.McManus , J.Le Engers , M. E.Mattmann , D. W.Engers , U. M.Le , C. W.Lindsley , C. R.Hopkins and M.Li , Probe Reports from the NIH Molecular Libraries Program [Internet] , 2013
- Wickenden, 2000, Mol. Pharmacol., 58, 591, 10.1124/mol.58.3.591 · doi:10.1124/mol.58.3.591 · Paper page
- Zilliox, 2017, Continuum, 23, 512
- Atri, 2019, J. Clin. Psychiatry, 80, MS18002AH3C
- Repovic, 2019, Continuum, 25, 655
- Sheppard, 2014, Acta Otorhinolaryngol. Ital., 34, 79
- Shin, 2019, Hum. Mutat., 40, 335
- Su, 2012, Evid. Based Complement. Alternat. Med., 2012, 803082
- Xu, 2002, Am. J. Physiol., 283, 664
- Dalby-Brown, 2013, Eur. J. Pharmacol., 709, 52, 10.1016/j.ejphar.2013.03.039 · DOI
- D. E. Furst and T.Munster , in Nonsteroidal ant-inflammatory drugs, disease modifying antirheumatic drugs, nonopioid analgesics and drugs used in gout , ed. B. G. Katzung , McGraw-Hill Book Company , New York , 2001 , pp. 596–623
- Liu, 2014, Zhongguo Yaolixue Tongbao, 30, 574
- Ma, 2014, J. Chin. Pharm. Sci., 23, 153
- Kim, 2015, Nat. Commun., 6, 8116, 10.1038/ncomms9116 · DOI · Paper page
- Bett, 2006, J. Physiol., 576, 755, 10.1113/jphysiol.2006.116012 · DOI
- Zaczek, 1998, J. Pharmacol. Exp. Ther., 285, 724
- Yang, 2000, J. Pharmacol. Exp. Ther., 294, 955
- Zeng, 2019, JRSM Cardiovasc. Dis., 8, 2048004019854919
- Nattel, 1984, J. Pharmacol. Exp. Ther., 229, 283
Cited by
A small-molecule activation mechanism that directly opens the KCNQ2 channel
Zhang, S.-Y., Ma, D., Wang, K., Li, Y., Yang, Z., Li, X., Li, J., He, J., Mei, L., Ye, Y., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01515-y · Cited by 32
“Efforts have been dedicated to identifying small molecules that enhance KCNQ2 currents, particularly at subthreshold voltages, in which increased KCNQ2 activity can effectively prevent abnormal or excessive neuronal firing 21,22 .”
Yan, Z., Zhong, L., Zhu, W., Chung, S. K., & Hou, P. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106765 · Cited by 33
Recent advances in the pharmacology of voltage-gated ion channels
Mateos, D. L., Harris, B. J., Hernández-González, A., Yarov-Yarovoy, V. M., & Wulff, H. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100090 · Cited by 31
Pinheiro, B. P., Müller, M. C., Bös, M., Guezguez, J., Burnet, M. W. M., Tornincasa, M., Rizzetto, R., Rolland, J., Liberati, C., Lohmer, S., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04915-5 · Cited by 21
Henton, A., Zhao, Y., & Tzounopoulos, T. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1070-22.2023 · Cited by 15
“KCNQ channels have been a successful target for drug development (Davoren et al., 2015; Manville and Abbott, 2018; Miceli et al., 2018; Seefeld et al., 2018; Ostacolo et al., 2020; Borgini et al., 2021).”
BackgroundNaznin, F., Waise, T. M. Z., & Fernyhough, P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03003-1 · Cited by 14
Hernandez, C. C., Tarfa, R. A., Miguel I. Limcaoco, J., Liu, R., Mondal, P., Hill, C., Duncan, K. R., Tzounopoulos, T., Stephenson, C. R. J., O'Meara, M. J., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128841 · Cited by 11
Self-citationCarotenuto, L., Keminer, O., Carleo, G., Zaliani, A., Leo, A., Citraro, R., De Sarro, G., Dirkx, N., Kaji, M., Weckhuysen, S., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70119 · Cited by 10
“In addition to retigabine analogues, Kv7 activators with different chemotypes have also been developed (Borgini et al., 2021).”
Cannabidiol counters the effects of a dominant-negative pathogenic Kv7.2 variant
Zhan, X., Drummond-Main, C., Greening, D., Yao, J., Chen, S. W. R., Appendino, J. P., Au, P. Y. B., & Turner, R. W. (2022) · iScience · doi:10.1016/j.isci.2022.105092 · Cited by 10
“However, it is possible that CBD could interact with other receptors or channels in tsA-201 cells that could invoke other factors that modulate Kv7 channels (i.e. PiP2, PKC, calmodulin, arachidonic acid, and ERK1-2) (Borgini et al., 2021; Greene and Hoshi, 2016; Hudson et al., 2019; Larsson et al., 2020a).”
BackgroundWurm, K. W., Bartz, F., Schulig, L., Bodtke, A., Bednarski, P. J., & Link, A. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200473 · Cited by 10
Insights into ion channels to identify drug target for neuropathic pain management
Sharma, S., Rana, P., Dhingra, N., & Kaur, T. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01899-4 · Cited by 11
“…diclofenac, primarily a COX inhibitor, has been shown to modulate K v 7, K Ca , and K ATP channels through allosteric interactions at the trans-membrane domain, suggesting that modulation of potassium channels contributes to its analgesic effects (Borgini et al. 2021; Beich et al. 2025).”
Zhang, B., Shi, X., Liu, X., Liu, Y., Li, X., Wang, Q., Huang, D., Zhao, W., Cui, J., Cao, Y., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101132 · Cited by 10
Lemke, J., Gollasch, M., Tsvetkov, D., & Schulig, L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2438226 · Cited by 6
Villegas-Esguevillas, M., Cho, S., Vera‐Zambrano, A., Kwon, J. W., Barreira, B., Telli, G., Navarro‐Dorado, J., Morales‐Cano, D., de Olaiz, B., Moreno, L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114952 · Cited by 7
Beirow, K., Jedamzik, J., Schulig, L., Wurm, K. W., Lemmerhirt, C. J., Hofstetter, R. K., Link, A., & Bednarski, P. J. (2023) · ChemMedChem · doi:10.1002/cmdc.202300145 · Cited by 6
Progression of KCNQ4 related genetic hearing loss: a narrative review
Zhang, X., Wang, H., & Wang, Q. (2021) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000112 · Cited by 5
Cooper, B. Y., Nutter, T. J., Flunker, L. D., & Bowers, C. M. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.10.003 · Cited by 3
Three-Step Synthesis of the Antiepileptic Drug Candidate Pynegabine
Sun, Y.-J., Gong, Y., Lu, S., Zhang, S., & Xu, S. (2023) · Molecules · doi:10.3390/molecules28134888 · Cited by 3
Chemali, L. E., Boutary, S., Liu, S., Liu, G. J., Middleton, R. J., Banati, R. B., Bahrenberg, G., Rupprecht, R., Schumacher, M., & Massaad-Massade, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137327 · Cited by 3
“2/3-selective channel openers will be safer and more efficient, efforts are underway to develop more subtype-selective compounds [19].”
BackgroundWang, X., Zhang, Y., Liu, H., Wang, J., Zhang, B., He, T., Zhang, H., Xiong, Z., Liu, X., Li, J., et al. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70334 · Cited by 2
“K V 7.5), among which K V 7.1 is found in the heart and subtypes K V 7.2 to K V 7.5 are widely distributed throughout the nervous system [8, 9].”
InfluentialBauer, C. K., Holling, T., Horn, D., Laço, M., Abdalla, E. M., Omar, O. M., Alawi, M., & Kutsche, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179690 · Cited by 3
“To date, no officially approved drug with a potent Q1E2 channel-blocking activity is known [40].”
BackgroundSun, H., & Undem, B. J. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001959 · Cited by 2
“Hundreds of newly synthesized, repurposed or naturally occurred K V 7 channel activators (openers) have been reported (Du et al., 2018; Miceli et al., 2018; Borgini et al., 2021).”
BackgroundMasliukov, P. M., Сальников, Е. В., & Порсева, В. В. (2025) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093025040039 · Cited by 1
“Electrophysiological data suggest that the differ(cid:2) ences in accommodation between phasic and tonic sympathetic neurons are due to the presence of the I M current in the former (Table 1) [11, 35].”
Kushner, J. K., Hoffman, P. B., Brzezinski, C. R., O’Neill, B. R., Hankinson, T. C., Wilkinson, C. C., Handler, M. H., Hoeffer, C. A., & Alexander, A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107252 · Cited by 1
“…of the M-current can stabilize the membrane potential, inhibit the initiation of action potentials, and decrease the probability of burst firing (Borgini et al., 2021; Carver and Shapiro, 2019; Knight et al., 2023; Kobayashi et al., 2008; Peretz et al., 2005; Schroeder et al., 2000; Yang et…”
Hill, C., & Wipf, P. (2026) · Tetrahedron Letters · doi:10.1016/j.tetlet.2026.156040 · Cited by 1
Self-citationHotta, N., Miyamoto, M., & Suzuki, K. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136460 · Cited by 1
“Retigabine is thought to stabilize the resting membrane potential and reduce neuronal excitability by activating KCNQ channels [32].”
BackgroundBehavior of KCNQ Channels in Neural Plasticity and Motor Disorders
Singh, S. P., William, M., Malavia, M., & Chu, X. (2022) · Membranes · doi:10.3390/membranes12050499 · Cited by 1
Zhang, B., Shi, X., Liu, X., Liu, Y., Wang, Q., Li, X., Cao, Y., Zhao, W., Wang, J., Zhang, Y., et al. (2024) · doi:10.22541/au.171828190.03748784/v1 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Hernández, C. C., Tarfa, R. A., Limcaoco, J. M. I., Liu, R., Mondal, P., Hill, C., Duncan, R. K., Tzounopoulos, T., Stephenson, C. R. J., O’Meara, M. J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4086889
Self-citationTherapeutic Targeting of Potassium Channels
Gamper, N. L., Huang, D., Qi, J., Dong, L., & Zhang, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_5 · Cited by 1
Elucidation of the zinc binding site in KCNQ channels
Zhang, S., Yang, X., Yang, M., Cao, Y., Shi, S., Gamper, N. L., & Gao, H. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70177
“Likewise, an increasing number of natural and synthetic compounds were identified as KCNQ modulators, of which the majority are activators (Borgini et al., 2021; Du et al., 2018; Jones et al., 2021; Liu et al., 2021).”
Targeting voltage-gated potassium channels for the treatment of genetic epilepsy
He, G., & Liu, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00060-1
Cholesterol and Cholesterol‐Derived Molecules Differentially Modulate Neuronal Kv7.2/7.3 Channels
Karabatak, E., Nematswerani, R., Meiritz, V., Rychlik, N., Seebohm, G., Glorius, F., & Budde, T. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70280 · Cited by 1
“Current strategies include structure‐based drug design and high‐throughput screening approaches, often guided by endogenous modulators such as lipids and steroid hormones as well as by rational designed benzamide‐related compounds [10, 11].”
Molecular Basis for Activation to Inhibition Switching in Kv7.2 Channel Modulators
Ciaglia, T., Carleo, G., Yang, Z., Matteo, F. D., Rosa, F. D., Smaldone, G., Gao, Z., D’Alì, M., Turcio, R., Ma, D., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.7948330
Molecular Basis for Activation to Inhibition Switching in Kv7.2 Channel Modulators
Ciaglia, T., Carleo, G., Yang, Z., Matteo, F. D., Rosa, F. D., Smaldone, G., Gao, Z., D’Alì, M., Turcio, R., Ma, D., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.7948330
Sun, S., Jia, Q., Bankar, G. R., Burford, K., Christabel, J., Clement, H. A., de Boer, G., Feng, Z., Hambira, C. M., Jackson, S. K., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00360
Metadata
- Authors
- Borgini, M., Mondal, P., Liu, R., & Wipf, P.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Wipf, Peter
- Venue
- RSC Medicinal Chemistry
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 12
- Issue
- 4
- Pages
- 483-537
- ISSN
- 2632-8682 (ISSN-L)
- PMC
- PMC8128042
- OpenAlex
- W3119057473
- Cited by
- 37
- References
- 386
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 1
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- RSC Medicinal Chemistry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1810623)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- Kv7 potassium channels, KCNQ channels, voltage-gated potassium channels, small molecule modulators, channel blockers, synthetic chemistry, medicinal chemistry, clinical properties
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.